Insider Selling: Krystal Biotech (NASDAQ:KRYS) Insider Sells $8,983,000.00 in Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $359.32, for a total value of $8,983,000.00. Following the completion of the sale, the insider owned 1,302,145 shares in the company, valued at $467,886,741.40. The trade was a 1.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Krystal Biotech Price Performance

NASDAQ KRYS traded down $13.23 during mid-day trading on Friday, reaching $358.24. 323,012 shares of the stock were exchanged, compared to its average volume of 204,795. The stock has a market cap of $10.60 billion, a P/E ratio of 44.89 and a beta of 0.54. Krystal Biotech, Inc. has a one year low of $136.73 and a one year high of $382.54. The stock has a 50 day simple moving average of $349.81 and a 200-day simple moving average of $307.38.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, topping analysts’ consensus estimates of $1.70 by $0.09. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%.The firm had revenue of $119.22 million during the quarter, compared to the consensus estimate of $120.93 million. Sell-side analysts anticipate that Krystal Biotech, Inc. will post 7.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on KRYS shares. TD Cowen lifted their target price on Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a report on Thursday, June 18th. Royal Bank Of Canada initiated coverage on Krystal Biotech in a report on Friday, August 14th. They set an “outperform” rating and a $400.00 price target on the stock. Wall Street Zen downgraded shares of Krystal Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Weiss Ratings lowered shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th. Finally, Chardan Capital upgraded shares of Krystal Biotech to a “strong-buy” rating in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $365.40.

Hedge Funds Weigh In On Krystal Biotech

A number of institutional investors have recently modified their holdings of KRYS. Corient Private Wealth LP lifted its holdings in shares of Krystal Biotech by 767.4% in the 2nd quarter. Corient Private Wealth LP now owns 30,558 shares of the company’s stock worth $11,357,000 after purchasing an additional 27,035 shares in the last quarter. HighTower Advisors LLC increased its stake in Krystal Biotech by 3.9% during the 2nd quarter. HighTower Advisors LLC now owns 2,129 shares of the company’s stock valued at $791,000 after purchasing an additional 80 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Krystal Biotech during the second quarter worth $3,865,000. California State Teachers Retirement System lifted its stake in shares of Krystal Biotech by 33,527.2% in the second quarter. California State Teachers Retirement System now owns 8,805,606 shares of the company’s stock valued at $3,272,780,000 after buying an additional 8,779,420 shares in the last quarter. Finally, denkapparat Operations GmbH acquired a new position in shares of Krystal Biotech during the second quarter valued at about $226,000. 86.29% of the stock is owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.